On Thursday, Xencor earned a positive adjustment to its Relative Strength (RS) Rating, from 65 to 82.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the best-performing stocks typically have an 80 or higher RS Rating as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Xencor is trying to complete a consolidation with a 25.41 entry. See if it can break out in volume at least 40% above average.
The company posted 0% earnings growth in its most recent report, while sales growth came in at -82%.
Xencor holds the No. 214 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
